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Abstract: Background: Nowadays, ionizing radiation is used for several applications in medicine, 
industry, agriculture, and nuclear power generation. Besides the beneficial roles of ionizing radia-
tion, there are some concerns about accidental exposure to radioactive sources. The threat posed by 
its use in terrorism is of global concern. Furthermore, there are several side effects to normal organs 
for patients who had undergone radiation treatment for cancer. Hence, the modulation of radiation 
response in normal tissues was one of the most important aims of radiobiology. Although, so far, 
several agents have been investigated for protection and mitigation of radiation injury. Agents such 
as amifostine may lead to severe toxicity, while others may interfere with radiation therapy out-
comes as a result of tumor protection. Metformin is a natural agent that is well known as an anti-
diabetic drug. It has shown some antioxidant effects and enhances DNA repair capacity, thereby 
ameliorating cell death following exposure to radiation. Moreover, through targeting endogenous 
ROS production within cells, it can mitigate radiation injury. This could potentially make it an ef-
fective radiation countermeasure. In contrast to other radioprotectors, metformin has shown modu-
latory effects through induction of several genes such as AMPK, which suppresses reduc-
tion/oxidation (redox) reactions, protects cells from accumulation of unrepaired DNA, and attenu-
ates initiation of inflammation as well as fibrotic pathways. Interestingly, these properties of met-
formin can sensitize cancer cells to radiotherapy. 
Conclusion: In this article, we aimed to review the interesting properties of metformin such as ra-
dioprotection, radiomitigation and radiosensitization, which could make it an interesting adjuvant 
for clinical radiotherapy, as well as an interesting candidate for mitigation of radiation injury after a 
radiation disaster. 
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DNA repair, mitochondria, AMPK, tumor resistance, cell cycle. 
INTRODUCTION 
 Nowadays, ionizing radiation is an inseparable agent in 
human life. Radiation is useful for several applications such 
as industrial, agricultural, nuclear power generation, diagnostic 
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and therapeutic medicinal procedures [1]. In contrast to these 
useful applications, there are some concerns about accidental 
exposure to radiation workers [2-4]. Incidents such as World 
War 2, Chernobyl nuclear weapon explosion, as well as 
some terrorist activities in recent years, are major concerns 
related to the use of radioactive agents [5]. Nowadays, the 
most important and widest application of ionizing radiation 
is related to its clinical applications for diagnosis of diseases 
as well as its therapeutic applications for cancers [6]. Usu-
ally, diagnostic applications of ionizing radiation have not 
led to any remarkable toxicity, however, high doses of radia-
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tion for therapeutic purposes could lead to significant side 
effects in normal tissues [7, 8]. 
 Normal tissue toxicity is a major limiting factor in the 
delivery of an effective radiation dose to tumor cells [9]. 
This issue is even more critical when a radiosensitive organ 
is located within the radiation field [10, 11]. Exposure of 
bone marrow cells leads to massive apoptosis, thereby caus-
ing lymphopenia and reduction of other blood cells, which 
affect the immune system potently [12-16]. The gastrointes-
tinal system is another sensitive organ to radiation. Exposure 
to a heavy dose of ionizing radiation during radiotherapy 
may lead to severe damages to the epithelial cells of gastro-
intestinal system, as well as some late effects such as chronic 
inflammation, ulcer and bleeding [17-20]. Some of these late 
effects could lead to death, some months to years after expo-
sure to high doses of ionizing radiation. Chronic inflamma-
tion in the lung may lead to pneumonitis, which occurs some 
months after radiotherapy or exposure to an accidental radia-
tion event (more than 7-8Gy) [21-24]. In higher doses of 
ionizing radiation, the incidence of fibrosis is possible [23, 
25-27]. Cardiovascular and cerebral disorders, as well as 
skin reactions are other important side effects to normal tis-
sues that may appear following radiotherapy or a radiation 
disaster [28, 29]. 
 So far, several chemical or natural agents have been pro-
posed for the management of normal tissue toxicity during 
radiotherapy [30, 31]. Amifostine is the most famous agent 
that has been proposed for the amelioration of xerostomia in 
head and neck patients. However, as a result of its high tox-
icity, it has not been able to protect most organs [32-35]. 
Hence, there is a need for the continuous search for low toxic 
and effective radiation modifiers. However, the possible pro-
tection of tumor cells is of utmost concern while administer-
ing several radioprotectors such as classic antioxidants [36-
39]. In the present review, we aimed to propose metformin 
as a radioprotector with potent anti-cancer effects. Further-
more, we proposed the potent redox modulatory effect of 
metformin as an appropriate radiation mitigator for applica-
tions in radiation disasters. 
MECHANISMS OF RADIATION-INDUCED 
TOXICITY 
Radiation-induced DNA Damage and Cell Death; Early 
Effects 
 DNA is the most critical macromolecule within cells 
while ionizing radiation is the most important clastogenic 
agents that can be used in medicine or some other applica-
tions. For a typical dose of ionizing radiation in conventional 
radiotherapy (2Gy per each fraction), more than 1000 single 
strand breaks (SSBs), more than 1000 base mutation and 
more than 20 double-strand breaks (DSBs) can occur within 
each exposed cell [29]. In some new radiotherapy techniques 
such as stereotactic radiotherapy, using higher doses of ion-
izing radiation could possibly lead to severe DNA damage in 
irradiated cells [40, 41]. The response of cells to DNA dam-
age is highly dependent on DNA damage response (DDR) by 
DNA repair enzymes [42-44]. Moreover, the expression of 
pro-apoptosis factors such as p53 and BAX affect cell death 
induction through apoptosis in some radiosensitive organs 
such as bone marrow and intestine [45-49]. 
 If cells are not able to complete the repair process of 
damaged DNA, cells may undergo death through different 
pathways such as mitotic catastrophe, apoptosis, necrosis, 
autophagy, and senescence [50, 51]. If the numbers of cell 
deaths are very high, it may lead to loss of organ function 
[52, 53]. For example, high apoptosis in bone marrow cells 
affects the immune system activities in patients that undergo 
radiotherapy or people that were exposed to an accidental 
radiation event [54-56]. Apoptosis and necrosis of stem cells 
in the tongue and intestine could lead to some problems in 
the digestion of food, which is a common side effect for pa-
tients with head and neck, as well as abdominal cancers [57-59]. 
RADIATION-INDUCED INFLAMMATION AND 
FIBROSIS; LATE EFFECTS 
 Although DNA damage and cell death occur some hours 
to days after irradiation [60, 61], evidences have shown that 
both oxidized DNA and dead cells trigger several signaling 
cascades that lead to severe toxicity in irradiated organs. The 
products of dead cells including apoptotic bodies and intra-
cellular contents that are released following necrosis, senes-
cence or autophagy are able to trigger tolerogenesis or in-
flammation by immune cells [41]. Apoptotic bodies are di-
gested by macrophages, thereby preventing inflammatory 
responses by lymphocytes. However, digestion of apoptotic 
bodies leads to the release of tolerogenic cytokines such as 
IL-10 and TGF-β [62]. On the other hand, disruption of cell 
membrane by necrosis leads to the release of some danger 
alarms such as HMGB1, uric acid, and oxidized nucleus or 
mitochondrial DNA (mtDNA), which trigger lymphocytes, 
macrophages and dendritic cells to release inflammatory 
cytokines [63, 64]. 
 Toll-like receptors (TLRs) are the most important recep-
tors for danger alarms that are released by dying cells or oxi-
dized DNA. It has been proposed that TLR2, TLR4, TLR5 
and TLR9 are the main receptors for releasing danger alarms 
by ionizing radiation [65-68]. Binding of danger alarms to 
TLRs leads to the upregulation of inflammatory mediators 
such as nuclear factor-kB (NF-kB), signal transducers and 
activators of transcription (STATs) as well as mitogen-
activated protein kinases (MAPKs), leading to the release of 
inflammatory cytokines by lymphocytes and macrophages 
[69-71]. Increased levels of IL-1, IL-2, IL-4, IL-6, IL-8, IL-
13, IL-18, IL-33, TNF-α and IFN-γ are the most important 
changes in the level of inflammatory cytokines following 
exposure to a high dose of ionizing radiation [72]. 
 Evidences have shown that pro-fibrotic cytokines such as 
IL-4, IL-13 and TGF-β through upregulation of pro-oxidant 
enzymes, induce continuous production of ROS, which me-
diate an increase in the level of fibrotic mediators such as 
alpha-smooth muscle actin (α-SMA) [73, 74]. These changes 
lead to the accumulation of collagen and fibronectin in inter-
cellular spaces, leading to tissue stiffness and appearance of 
fibrosis [75]. On the other hand, inflammatory cytokines 
stimulate the production of prostaglandins, nitric oxide (NO) 
and ROS, leading to symptoms of pain and inflammation in  
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irradiated tissues [76]. Both pro-inflammatory and pro-
fibrotic cytokines are able to induce reduction/oxidation (re-
dox) reactions through stimulation of pro-oxidant enzymes 
and mitochondria, leading to further DNA oxidation and cell 
death [77]. This triggers upregulation of inflammation and 
fibrosis mediators in a positive feedback loop [78]. Chronic 
oxidative injury following exposure to radiation plays a key 
role in the development of fibrosis and inflammation in sev-
eral organs. This may lead to disruption of organ function 
and some signs such as ulcer and bleeding, which can poten-
tially affect the quality of life of patients who had undergone 
radiotherapy [79]. 
METFORMIN 
 Metformin originates from Galega Officinalis (French 
lilac) and was first identified in 1922 by Emil Werner and 
James Bell. This herb is rich in guanidine, a blood glucose 
lowering agent (a substantial agent in metformin). Some 
studies conducted in 1950 and later, revealed some other 
properties of metformin such as antiviral, polyuria, bacte-
riostatic, halitosis etc. Metformin is approved by the U.S. 
Food and Drug Administration (FDA) for type 2 diabetes 
and is the most used anti-diabetic drug worldwide [80]. 
 
Fig. (2). Chemical structure of metformin. 
 
 In addition to the anti-diabetic effect of metformin, it has 
been found to possess some interesting properties such as 
antioxidant, anticancer, genomic stability, anti-inflammation 
and anti-fibrosis, which are interesting for its use as an adju-
vant in oncology [81]. These properties propose its use for 
protecting normal tissues against the toxic effects of chemo-
therapy and radiotherapy, as well as tumor suppression. 
POTENTIAL ANTIOXIDANT EFFECTS OF 
METFORMIN 
 Some experimental studies have confirmed the antioxi-
dant effect of metformin. As shown in Fig. 1, metformin is a 
hydrogen-rich agent. It is well known that hydrogen is able 
to interact with free radicals and neutralize their reactivity 
[82, 83]. In addition to the direct antioxidant effect of met-
formin, studies have revealed that it can scavenge free radi-
cals through stimulation of antioxidant defense in cells 
[84,85]. A study by Obi et al. showed that treatment of dia-
betic rats with metformin alleviates oxidative injury through 
upregulation of superoxide dismutase (SOD), glutathione 
(glutathione), and catalase (CAT) [86]. Human studies have 
also shown that the use of metformin for diabetic patients 
reduces the level of oxidative stress markers remarkably  
[87-89]. 
 It seems that the most potent effect of metformin against 
oxidative stress is related to the modulation of cellular me-
tabolisms, following exposure to an oxidant agent. Met-
formin is a potent inhibitor of redox reactions through sup-
pression of mitochondria electron chain 1 (ETC1). In re-
sponse to oxidant stimulus, mitochondria amplify the pro-
duction of superoxide, leading to mutation in mtDNA, and 
mitochondrial malfunction, as a consequence. Inhibition of 
ETC1 by metformin can inhibit increased superoxide pro-
duction and attenuate redox activities within cells [90, 91]. 
 
Fig. (1). Molecular mechanisms of normal tissue toxicity following exposure to ionizing radiation. 
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 In addition to mitochondria, metformin has a potent in-
hibitory effect on regulation of NADPH oxidase enzymes. 
NADPH oxidase is composed of 7 subfamilies; NOX1-5 and 
dual oxidase 1 and 2 (duox1&2). These enzymes are upregu-
lated following exposure of cells to stress conditions such as 
oxidative stress and inflammation. All of these enzymes are 
able to generate superoxide and hydrogen peroxidase in re-
sponse to inflammation and oxidative stress. NOX1-5 genes 
are stimulated by some cytokines such as IL-1 and TGF-β, 
while duox1&2 may be upregulated by IL-4, IL-13 and IFN-
γ. Metformin has shown ability to attenuate the upregulation 
of NOX family enzymes, leading to protection against oxida-
tive injury and subsequent consequences such as fibrosis 
[85]. It is possible that metformin via reduction of macro-
phage activity decreases the release of cytokines and upregu-
lation of NOX genes [92]. Metformin also has shown ability 
to inhibit the upregulation of duox1&2 in rat’s lung and heart 
tissues. This was associated with amelioration of inflamma-
tory cells’ infiltration as well as reduction of IL-4 level [93, 94]. 
IMMUNE SYSTEM REGULATION BY METFORMIN 
 Immune system responses play a central role in the re-
sponse of both normal tissues and tumor cells to therapeutic 
strategies like radiotherapy, chemotherapy and immunother-
apy [29]. Metformin has shown interesting immune system 
modulation properties that can improve the response of tu-
mor cells and amelioration of normal tissue toxicity. As 
mentioned in the previous section, the mitochondria are main 
target for metformin. Continuous ROS production by the 
mitochondria further amplifies oxidized DNA and cell death 
that activate redox reaction through stimulation of inflamma-
tory mediators [77, 95]. It has been confirmed that the mito-
chondria have a close link with other pro-oxidant enzymes 
such as cyclooxygenase-2 (COX-2), inducible nitric oxide 
synthase (iNOS), NADPH oxidase etc [96]. It has also been 
shown that metformin stimulates the activities of cytotoxic 
lymphocytes against cancer cells [97, 98]. It has been re-
vealed that suppression of NF-κB and STAT-3 by metformin 
are involved in the inhibition of inflammatory cytokines as 
well as cellular transformation [99, 100]. These properties of 
metformin make it a candidate for the prevention and treat-
ment of some immune-based diseases [101, 102]. 
DNA REPAIR BOOSTING BY METFORMIN 
 Enhancing DNA repair response to genotoxic agents is 
an interesting effect of metformin. In addition to the antioxi-
dant and anti-inflammatory effects of metformin that prevent 
DNA damage and cell death, it can also trigger enzymes 
involved in DNA repair process to further ameliorate ge-
nomic instability [103, 104]. It seems that AMPK plays a 
central role in boosting DNA repair response to genotoxic 
agents. AMPK is a stimulator for ataxia telangiectasia mu-
tated (ATM), a central regulatory gene in DNA repair proc-
ess. ATM induces phosphorylation of γH2AX in response to 
DNA damage, by initiating the activation of enzymes in-
volved in DNA damage response [105]. Also, AMPK phos-
phorylate p53 leads to the arrest of cell cycle [106, 107]. 
 Turacli et al. evaluated the potential modulatory effect of 
metformin on base excision repair (BER) pathway genes in 
diabetic patients. Patients received 2000 mg metformin per 
day (2×1000 mg) for 6 months. Afterwards, blood samples 
were collected to detect the protein level of DNA polymerase 
beta as well as X-ray repair cross-complementing Gene1 
(XRCC1), two important proteins that are involved in BER 
pathway of DNA repair. Their results showed no significant 
change in the level of DNA polymerase beta for diabetic 
patients with or without metformin. Although the level of 
XRCC1 and p53 were reduced in diabetic patients without 
metformin, patients who received metformin showed a re-
markable increase for both of them [108]. 
METFORMIN AS RADIOPROTECTOR 
 The antioxidant and anti-apoptosis activity of metformin, 
as well as enhancing DNA repair responses are interesting 
properties that can help attenuate the initiation of inflamma-
tion and fibrosis following exposure to radiation. As earlier 
mentioned, interactions between pro-inflammatory and pro-
fibrotic cytokines with redox mediators play central role in 
chronic oxidative stress. Preventing DNA damage and cell 
death, as well as inhibition of redox activity are interesting 
effects of metformin that make it a potential candidate for 
the alleviation of early and late effects of radiotherapy. In 
recent years, some studies have been conducted to evaluate 
the potential radioprotective effect of metformin in different 
cells [81]. Xu et al. evaluated the potential radioprotective 
effect of metformin on mice bone marrow stem cells. Mice 
were treated with 250 mg/kg metformin 1 day before and 1 
week after whole-body irradiation with 4Gy. Results showed 
that while irradiation led to chronic ROS production and 
oxidative DNA damage in hematopoietic stem cells (HPSc) 
for some weeks, treatment with metformin potently reduced 
ROS production and subsequent DNA damage. Further 
analyses showed that the upregulation of NADPH oxidase 4 
(NOX4) is mainly responsible for chronic oxidative stress. 
Metformin could suppress the upregulation of NOX4. 
Moreover, as NOX4 plays a key role in the senescence of 
stem cells, metformin administration reduced senescence, 
however, it could not mitigate apoptosis in HPSc. Further-
more, metformin showed increased activity of antioxidant 
enzymes such as SOD, GPx and CAT [109]. 
 A study by Cheki et al. revealed the radioprotective ef-
fect of metformin on human lymphocyte cells before irradia-
tion with different doses of 1, 2, 3 and 4Gy as well as treat-
ment with two different metformin concentrations (10 and 50 
µM). This study showed that treatment of lymphocytes with 
50 µM metformin did not cause any genotoxicity such as 
micronuclei formation, and increase in other DNA damage 
markers like dicentrics, acentrics, and rings. Their results 
also showed that treatment with metformin before irradiation 
ameliorates micronuclei formation and induction of nucleo-
plasmic bridges, as well as increased proliferation index of 
irradiated cells. Moreover, analysis of metaphase showed 
that the numbers of dicentrics, acentrics, and rings were re-
duced significantly. In contrast to another study by Xu et al., 
this study showed that metformin attenuates apoptosis induc-
tion in irradiated cells. The protective effect of metformin for 
all parameters was more remarkable for 50 µM compared to 
10 µM [110]. It has been found that metformin treatment 
reduces BAX to Bcl-2 ratio, thus reducing apoptosis induc-
tion in human lymphocytes [111]. In a human study, it has 
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been shown that metformin treatment can improve the de-
creased numbers of peripheral blood cells such as complete 
blood count (CBC), absolute neutrophil count (ANC), abso-
lute lymphocyte count (ALC) and platelet numbers follow-
ing 131I therapy for thyroid cancer therapy [112]. By contrast 
to these studies, a study by Mota et al. showed no protective 
effect of metformin for radiation sensorineural hearing loss 
in in vitro pig models [113]. In addition to this study, met-
formin has shown that through stimulation of AMPK, it ame-
liorates oxidative injury and elevates antioxidant defense 
against toxicity of radiation plus cisplatin [114]. 
METFORMIN AS A RADIATION MITIGATOR 
 Mitigation of radiation injury is essential for the treat-
ment of exposed people to an accidental radiological or nu-
clear disaster. In this situation, exposed people may undergo 
hematopoietic or gastrointestinal system syndrome, which 
could lead to death after some days to weeks. Also, exposure 
of other organs such as skin, heart, kidney or lung to a high 
dose of radiation may lead to organ failure, months to years 
after exposure [115-117]. So far, some studies have shown 
that treatment with some antioxidants or redox modulatory 
agents after exposure can mitigate radiation injury in these 
organs [3, 118]. Metformin, a potent inhibitor of redox sys-
tem has shown promising properties for mitigation of radia-
tion toxicity. For the first time, in 2014, Miller et al. pro-
posed the potential mitigatory effect of metformin in both in 
vitro and in vivo models. They evaluated spleen clonogenic 
assay for irradiated mice with or without metformin. For 
evaluating clonogenic assay, the irradiated bone marrow 
cells were injected into other mice. The stem cells whose 
clonogenic abilities were preserved were able to divide and 
develop new colonies in the spleen. They injected 400 mg/kg 
metformin 30 min before irradiation with 7Gy, gave a 1.8-
fold increase for spleen clonogenic assay. Similar results 
were obtained when metformin was administered 24 h after 
irradiation. Interestingly, when metformin in combination 
with captopril, MESNA or N-acetyl-cysteine was adminis-
tered to mice, clonogenic assay showed an increase by more 
than 2.5 fold. In vitro studies also showed that post-exposure 
treatment with metformin or in combinational forms in-
creases survival of SA-NH murine sarcoma, human mi-
crovascular endothelial cells (HMEC) and mouse embryo 
fibroblasts (MEF) after irradiation with 4Gy [119]. 
 Lung pneumonitis and fibrosis is a threat following nu-
clear disasters as well as radiological terrorism. Mitigation of 
lung injury following exposure to an acute dose of radiation 
has been examined by several studies [4, 120-122]. Wang et 
al., revealed the protective effect of metformin against radia-
tion-induced fibrosis in rat’s lung tissues. Rats were irradi-
ated with 20Gy X-rays followed by daily treatment with 200 
mg/kg metformin (starting from 4 h after irradiation to 2 
weeks). Their results showed that while exposure to radia-
tion led to an increase in the rate of respiration, treatment 
with metformin reversed it significantly. Moreover, met-
formin treatment caused the amelioration of interstitial septal 
thickening, fibrosis and inflammatory markers. It has been 
proposed that metformin, through modulation of TGF-β–
Smad1/2 pathway alleviates differentiation of fibroblasts and 
accumulation of collagen in irradiated lung tissues [123]. 
 Skin injury is a common and serious side effect that can 
be observed after radiotherapy or a nuclear event. Evidences 
from Chernobyl nuclear explosion showed occurrence of 
skin toxicity in exposed people [124]. Mitigation of radia-
 
Fig. (3). Mechanisms of radioprotection and radiomitigation by metformin on normal cells/tissues. 
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tion-induced skin injury is an interesting issue in radiation 
biology. Treatment with metformin has shown ability to 
mitigate radiation-induced skin injury. For confirmation of 
this issue, a 1 x 1 cm2 mice skin was irradiated with 30 or 
50Gy orthovoltage X-rays followed by treatment with met-
formin (with a dose of 50 or 100 mg/kg administered thrice a 
day for 1 week after irradiation). Results showed that met-
formin has ability to prevent deposition of collagen and at-
tenuates the increased level of pro-inflammatory and pro-
fibrosis cytokines such as TGF-β, IL-6, C-C motif 
chemokine 11 (CCL11), STAT-3 and oxidative injury. Re-
sults showed that suppression of FOXO-3 by metformin 
plays a key role in amelioration of skin fibrosis [125]. 
METFORMIN AS RADIOSENSITIZER 
Mechanisms of Tumor Resistance to Radiotherapy 
 Experimental and pre-clinical studies have shown that 
radiotherapy leads to several changes in the tumor microen-
vironment which stimulates tumor adaptation to radiation, 
leading to a reduction in therapeutic efficiency [126-128]. 
This may also lead to invasion and spread of tumor cells 
which facilitate metastasis in patients. For better manage-
ment of tumor response to radiotherapy, we need to under-
stand the mechanisms of tumor resistance to radiotherapy. 
Tumor microenvironment includes various types of cells 
such as tumor cells, macrophages, lymphocytes, dendritic 
cells, endothelial cells, vascular, etc. [129, 130]. Amongst 
the different cells within the tumor microenvironment, endo-
thelial cells are highly sensitive to ionizing radiation [131]. 
Interaction of these cells with ionizing radiation leads to 
apoptosis. Also, therapeutic doses of radiotherapy can cause 
massive injury to microvascular, leading to disruption of 
blood supply. This is associated with hypoxia and necrosis of 
some tumor cells. Apoptosis and necrosis lead to release of 
inflammatory and pro-fibrotic cytokines. On the other hand, 
vascular injury and hypoxia lead to upregulation of angio-
genesis genes such as hypoxia-inducible factor-1 (HIF-1), 
vascular endothelial growth factor (VEGF), intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1) [132, 133]. 
 HIF-1 and VEGF are the most potent stimulators of angi-
ogenesis in tumor cells. The expression of these genes has a 
direct relationship with radioresistance of tumor [134, 135]. 
Also, these factors are involved in invasion and metastasis of 
cancer cells [136]. On the other hand, increased level of both 
pro-fibrosis and pro-inflammatory cytokines lead to the in-
creased expression of several inflammatory mediators such 
as NF-kB, which increases cell resistance to apoptosis [137, 
138]. Moreover, increased TGF-β and IL-10 which occur 
following irradiation, lead to attenuation of the activities of 
lymphocytes and dendritic cells against cancer cells [139, 
140]. Hence, inhibition of inflammation and angiogenesis 
factors in tumor cells is an interesting idea for sensitization 
of cancer cells to radiotherapy [141, 142]. Some clinical trial 
studies have shown promising results following inhibition of 
COX-2, NF-kB, TGF-β and etc [30]. However, clinical stud-
ies have shown high toxicity following selective inhibition of 
VEGF [143]. Metformin, a natural and low toxic agent has 
shown promising tumor suppressive effects that could make 
it a potential adjuvant for several cancers. It has also been 
confirmed that metformin, through activation of AMPK, 
induces regulation of several antitumor signaling pathways 
[143, 144]. 
THE PLEIOTROPIC ACTIONS OF METFORMIN IN 
NORMAL/CANCER CELLS 
 An interesting property of metformin is its differential 
effects on normal and cancer cells. One of the interesting 
effects of metformin is the changes in ROS levels of both 
normal and cancer cells. In cancers, ROS can promote dif-
ferentiation and division in lower levels, while high produc-
tion of it leads to cell death [145]. Metformin has shown the 
ability to disrupt redox balance in some cancer cells, leading 
to more ROS production, DNA damage and cell death [146, 
147]. However, metformin reduces oxidative injury in nor-
mal cells through inhibition of endogenous production of 
ROS. Inhibition of NADPH oxidase and mitochondria are 
known protective effects of metformin against oxidative 
stress [148]. One of the important properties of metformin is 
the inhibition of inflammation in both normal and tumor 
cells [149-151]. As earlier mentioned, inflammation leads to 
chronic oxidative stress and is responsible for the appearance 
of severe side effects of radiotherapy such as pneumonitis, 
fibrosis, dermatitis, mucositis, vascular injury, and others. 
On the other hand, upregulation of inflammatory mediators 
such as COX-2, HIF-1, NF-kB, mTOR, and STATs induces 
proliferation, angiogenesis and more survival. Thus, they are 
responsible for the radioresistance of most cancer cells 
[152]. Targeting of these inflammatory mediators has been 
proposed for radioprotection of normal tissues as well as 
radiosensitization of tumors. Metformin through suppression 
of these mediators induces apoptosis and autophagy in can-
cer cells [153, 154]. It has been reported that metformin sup-
presses mTOR via activation of AMPK, leading to auto-
phagy of pancreatic cancer cells [155]. 
 Mitochondria targeting is an interesting strategy for can-
cer sensitization. The Mitochondria produce ROS in re-
sponse to radiation and most chemotherapy drugs, leading to 
oxidative injury in normal tissues. On the other hand, cancer 
cells need more ATP production by mitochondria, because 
of high proliferation rate [156-158]. Inhibition of MTC1 in 
mitochondria is a strategy for sensitization of tumor cells 
[159]. It has been shown that treatment of MCF-7 cells with 
metformin leads to depletion of ATP and sensitization of 
cells to doxorubicin [160]. Andrzejewski et al. showed that 
metformin can inhibit mitochondrial respiration and citric 
acid cycle, leading to insufficient energy supply in tumor 
cells [161]. It is widely known that that tumor cells need 
glucose for proliferation, metformin via inhibition of cell 
respiration reduces the growth of tumor cells [162]. 
EVIDENCES ON RADIOSENSITIVE EFFECTS OF 
METFORMIN ON CANCER CELLS 
 So far, several in vitro and in vivo studies have confirmed 
the radiosensitive effect of metformin on different cancer 
cells. Metformin has shown the ability to target cancer cells 
without any toxicity to normal cells [163]. Studies have 
shown some mechanisms for radiosensitization of metformin 
such as targeting mitochondria, changes in tumor metabo-
lism, increasing ROS production, targeting DNA repair, 
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change in cell cycle distribution, and oxygenation of hypoxic 
cells. 
Disruption of Tumor Cells Metabolism 
 An interesting effect of metformin is targeting of mito-
chondria and other metabolic pathways within cells that are 
necessary for tumor growth. The mammalian target of ra-
pamycin (mTOR) is one of the most important genes that can 
shift metabolism of cells from catabolic to anabolic and 
plays a key role in resistance of tumor cells. Some studies 
proposed that by contrast to normal tissues, metformin is 
able to increase metabolism of ROS in tumor cells, leading 
to increased apoptosis of tumor cells [164]. Metformin has 
shown ability to reduce mitochondria activity through sup-
pression of MTC1, leading to ATP deprivation and inhibi-
tion of growth in hepatoma cancer cells [165]. A study by 
Song et al. revealed the radiosensitive activity of metformin 
in both in vitro and xenograft models. They showed that 
treatment of mouse fibrosarcoma and MCF-7 cells with met-
formin can inhibit proliferation of these cells. Also, when 
cells were incubated with 1 or 5 µM metformin before irra-
diation with 0-8Gy X-rays, the cells’ survival reduced sig-
nificantly compared to cells irradiated without metformin 
treatment. The suppressing effect of metformin showed a 
dose-dependent manner. Molecular analysis showed that 
metformin, through activation of AMPK, suppresses mTOR 
and its downstream genes such as S6K1 and 4EBP1. Met-
formin showed that through direct killing of cancer stem 
cells, it inhibits the growth of both mouse fibrosarcoma and 
MCF-7 cells [164]. 
 Mitochondria targeting by metformin is an interesting 
effect of metformin that can sensitize cells to ionizing radia-
tion. A study by Cheng et al., evaluated the role of mito-
chondria in sensitization of pancreatic tumor cells to radia-
tion. Human pancreatic cancer cells were treated with 0.1 to 
2 µM metformin or 0.1 to 1 µM meto-Met10 (an analogue of 
metformin) and irradiated with up to 6Gy X-rays. Results 
showed that both metformin and meto-Met10 inhibit the pro-
liferation of pancreatic cancer cells, while meto-Met10 was 
most effective. Moreover, both metformin and meto-Met10 
could attenuate the respiration of mitochondria in a dose-
dependent manner. This study showed that metformin and 
meto-Met10, through inhibition of ETC1 in mitochondria, 
increased the production of superoxide in pancreatic cancer 
cells, while it does not cause ROS production in normal 
cells. Meto-Met10 is more effective for mitochondria and cell 
growth targeting compared to metformin [166]. 
TARGETING OF DNA REPAIR AND CELL CYCLE 
 Metformin and its analogues have shown ability to in-
hibit cell growth through cell cycle arrest. Moreover, by con-
trast to its effect on normal cells, metformin has been shown 
to increase the level of ROS and suppresses DNA repair en-
zymes in cancer cells, thus induces delay of cell proliferation 
and tumor growth, as well as increased induction of cell 
death via accumulation of unrepaired damaged DNA [167]. 
Cheng et al. showed the inhibitory effect of metformin and 
meto-Met10 on the growth of pancreatic cancer cells. They 
showed that metformin as well as meto-Met10, through acti-
vation of AMPK, reduces the activity of cyclin D, leading to 
cells’ arrest in G1 and inhibition of cell division [166]. Arrest 
in G1 phase of cell cycle has been revealed for hepatocellular 
carcinoma (HCC) cells when cells were treated with met-
formin before exposure to gamma or carbon radiations. Irra-
diation of HCC cells leads to stopping of cell cycle in G2, 
while metformin reduces arrest in G2 and increases the num-
ber of G1 cells. It is supposed that metformin, through induc-
tion of DSBs in HCC cells, causes a delay in cell cycle pro-
gression. Also, metformin via targeting mTOR may inhibit 
proliferation of these cancer cells [168]. 
 Cancer cell cycle arrest in G2 by metformin has been 
observed in several studies. Fasih et al. revealed the radio-
sensitization effect of metformin on pancreatic cancer cells. 
Their study showed that radiation causes a G2/M arrest as 
well as a decrease in G0/G1-phase cells. However, metformin 
treatment did not change the distribution of cells compared 
to radiation alone. Meanwhile, metformin treatment before 
irradiation leads to more induction of DSBs compared to 
radiation alone. Authors suggested that activation of AMPK 
is necessary for sensitization of cancer cells to radiation 
[169]. It has been revealed that metformin, through suppres-
sion of RAD51 in these cells, attenuates homologous recom-
bination (HR) pathway, leading to accumulation of unre-
paired DSBs. Moreover, metformin abrogates kinases of the 
G2 point, leading to increasing mitotic catastrophe [170]. 
Similar results were obtained by Jeong et al. on colorectal 
cancer cells and xenografts. They also showed that met-
formin treatment attenuated the expression of HR DNA re-
pair pathway genes such as Rad50, RAD51, ERCC1, 
MRE11, BRCA1 and BRCA2 [171]. Accumulation of cells 
in G2/M phase of cell cycle following metformin treatment 
and irradiation has also been revealed for hepatoma cells. 
This was associated with remarkable induction of DSBs as 
well as 80% reduction in cell viability [165]. 
 In contrast to these studies, Muaddi et al., in an in vitro 
study showed that treatment of A549 and HCT116 cells with 
metformin may lead to a low protective effect against radia-
tion. They showed that AMPK and p53 activation are in-
volved in this protective effect. Inhibition of AMPK and p53 
in metformin-treated cancer cells led to significant decreases 
in survival for both A549 and HCT116 cells [172]. 
TUMOR OXYGENATION 
 From several years ago, it has been well known that hy-
poxia is one of the most important players for tumor resis-
tance to radiotherapy. Hypoxia increases survival of irradi-
ated cells and also triggers several signaling pathways which 
are involved in tumor angiogenesis, growth and metastasis. 
Therefore, inhibition of hypoxia can play a key role in cancer 
therapy, especially through radiotherapy. It has been reported 
that some metformin targets such as mTOR are involved in 
tumor hypoxia [173]. Some studies have shown that met-
formin facilitates tumor cell killing through oxygenation of 
hypoxic cells within the tumor [174, 175]. Pra et al., showed 
that metformin has ability to sensitize xenograft prostate 
cancer cells by augmenting the oxygenation of hypoxic can-
cer cells. Metformin can reduce the oxygen consumption by 
cells with high concentration of oxygen, thereby increasing 
the diffusion of oxygen to more distant cells from tumor ves-
sels [176]. Increasing oxygenation of tumors following met-
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formin treatment has been confirmed using 2-nitroimidazole 
hypoxia markers, positron emission tomography (PET) and 
immunohistochemistry in prostate and colorectal cancer 
xenografts [177]. 
CLINICAL EVIDENCES OF METFORMIN IN 
RADIOTHERAPY 
 Metformin is an FDA approved an anti-diabetic drug that 
is used by millions of people worldwide. Also, there are sev-
eral patients with cancer and diabetes that use metformin or 
other anti-diabetic drugs during radiotherapy. Emerging evi-
dences have shown an anti-cancer effect of metformin in 
patients with diabetes [178-186]. Some studies have been 
conducted to evaluate the possible effect of metformin usage 
in preventing side effects of radiotherapy to normal tissues 
or preventing tumor regression and patient survival [104, 
187]. Although the numbers of these studies are limited, 
their results are promising. A study by Ferro et al., evaluated 
the incidence of dermatitis in patients with breast cancer who 
had undergone radiotherapy. Patients included people with 
diabetes that used metformin or other alternative drugs. Re-
sults showed a 56% incidence of desquamation in patients 
who received metformin compared to 49% desquamation in 
non-diabetic patients. Interestingly, diabetic patients who 
received other alternative anti- diabetic drugs showed only 
32% incidence of desquamation [188]. 
 Metformin has shown inhibitory effect on tumor progres-
sion of patients with hepatocellular carcinoma. Patients with 
diabetes type 2 that received 500 to 2000 mg metformin per 
day were compared to other diabetic patients with same can-
cer that did not receive metformin. All patients were treated 
with hypofractionated radiotherapy or stereotactic body ra-
diotherapy (SBRT). A three-year follow-up showed that pa-
tients who used metformin had a 39% higher survival com-
pared to patients who did not receive metformin [189]. Met-
formin also has shown preventive effects on rectal cancers 
[183, 190-194]. A clinical study by Young et al., showed 
that metformin has a synergic effect on rectal tumor control 
by radiotherapy. Their study involved non-diabetic patients 
as well as diabetic patients with rectal cancer who had used 
metformin or other anti-diabetic drugs. Patients received 
radiotherapy and capecitabine or 5-fluorouracil (FU) for can-
cer treatment. Their results showed a significant increase in 
tumor response for patients who used metformin compared 
to other anti-diabetic drugs. Also, tumor response was more 
obvious for patients who used metformin compared to non-
diabetic patients who did not use metformin or other anti-
diabetic drugs [195]. Wink investigated the possible synergic 
effect of metformin on the therapeutic ratio of chemo/ 
radiation therapy for patients with NSCLC. Patients were 
treated with cisplatin, carboplatin or etoposide and radiotherapy 
with at least 50 Gy. A five-year follow-up showed a significant 
increase in survival of patients with metastasis, locoregional 
recurrence and progression-free survival, while there was no 
improvement in the overall survival [196]. 
CONCLUSION 
 As mentioned in this review, metformin has interesting 
properties that could make it a potential adjuvant for radio-
therapy. This is due to its radioprotective and radiosensitive 
effects as revealed in several in vitro and in vivo experi-
ments. Some studies have revealed the antioxidant effects of 
metformin against ionizing radiation, however, its main ef-
fect seems to be related to stimulating DNA repair pathways 
such as BER and HR pathways through upregulation of 
AMPK. In addition, metformin is a potent inhibitor of mito-
chondria, which plays a central role in chronic oxidative 
stress following exposure to ionizing radiation. Suppression 
of endogenous ROS production by mitochondria as well as 
other pro-oxidant enzymes such as NADPH oxidase can re-
duce oxidized DNA and cell death after exposure to radia-
tion. Metformin has shown that through modulation of these 
mediators, it ameliorates chronic oxidative injury, inflamma-
tion and fibrosis in different organs and cells. Redox modu-
 
Fig. (4). Molecular mechanisms of radiation sensitization of tumor cells by metformin. 
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lation by metformin is a promising property for mitigation of 
radiation injury after a radiological terror, nuclear explosion 
or an accidental radiation event that is possible in industrial 
or medical applications. Experimental studies have proposed 
that metformin inhibits increased production of ROS by he-
matopoietic stem cells, which is very crucial for the mitiga-
tion of hematopoietic failure and death because of lym-
phopenia and increased risk of infection. 
 The most limiting factors for using a radioprotector in 
radiotherapy are high toxicity and possible protection of tu-
mor cells. Although amifostine has received FDA approval 
for reducing xerostemia and mucositis in patients with head 
and neck cancers, its high toxicity could lead to discontinua-
tion of radiotherapy, thereby increasing the possibility of 
tumor regression. On the other hand, the use of classical an-
tioxidants for normal tissue preservation during radiotherapy 
has its risks in terms of protection of tumor cells and failure 
of radiotherapy outcomes. Metformin has shown that in ad-
dition to the protection of normal cells, it is able to sensitize 
cancer cells to radiation, thus augments therapeutic ratio of 
radiotherapy. Inhibition of mitochondria and some related 
genes like mTOR can disrupt the metabolism of tumor cells. 
Tumor cells need a high concentration of oxygen because of 
its high proliferation rate compared to normal cells, leading 
to hypoxia in distant cells to vascular. As hypoxia causes the 
resistance of cancer cells to radiotherapy, as well as leading 
to upregulation of some angiogenesis factors such as HIF-1 
and VEGF, targeting of angiogenesis is one of the most in-
teresting methods for tumor sensitization to radiotherapy. 
Metformin via attenuation of cell metabolism and oxygen 
consumption, causes oxygenation of hypoxic cells, leading 
to radiosensitization of cancer and attenuation of tumor 
growth. Metformin is also able to induce tumor growth inhi-
bition through increasing DNA damage and accumulation of 
cells in G1 or G2 phase of cell cycle, which are more sensi-
tive to ionizing radiation. 
 Results of in vitro and murine models’ studies have 
shown that metformin may be an effective adjuvant for ra-
diotherapy. Although clinical evidences for the radioprotec-
tive effect of metformin are limited, emerging evidences 
have emphasized its potential anti-tumor activity on different 
cancers such as breast, rectal and lung cancers. As metformin 
has potent anti-apoptosis effect on normal cells, evaluating 
metformin on blood parameters and its side effects on the 
gastrointestinal system such as mucositis and enteritis for 
patients with abdomen/pelvis cancers could prove useful. 
Results of clinical studies can aid this hypothesis and may be 
used in the future for clinical radiotherapy. 
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